Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 549Neoplasms 384Carcinoma, Non-Small-Cell Lung 319Colorectal Neoplasms 290Lung Neoplasms 239Prostatic Neoplasms 219Carcinoma, Hepatocellular 212Stomach Neoplasms 158Pancreatic Neoplasms 151Leukemia, Myeloid, Acute 139Multiple Myeloma 130Uterine Cervical Neoplasms 127Recurrence 116Rectal Neoplasms 112Ovarian Neoplasms 105Neoplasm Metastasis 104Squamous Cell Carcinoma of Head and Neck 97Head and Neck Neoplasms 89Esophageal Neoplasms 85Triple Negative Breast Neoplasms 84Glioblastoma 80Small Cell Lung Carcinoma 79Endometrial Neoplasms 79Colonic Neoplasms 78Brain Neoplasms 78Melanoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Glioma 62Motor Activity 60

Interventions

trifluridine tipiracil drug combination 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × mCRC × Clear all
NCT07543471 2026-04-24

PK similarity

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
387 enrolled

mCRC

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting
37 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡